Mayo Clinic Infectious Diseases
Mayo Clinic Infectious Diseases

@MayoClinicINFD

5 Tweets 2 reads Apr 22, 2023
#IDBR #MayoIDQ
#Fusarium sp. was isolated in a culture of tissue biopsy of a non-healing leg ulcer. Biopsy: invasive fungal elements in the dermis. It was resistant in vitro to #AmphoB and #voriconazole.
Which of these novel drugs is most active vs Fusarium species?
Suggested answer:
#Fosmanogepix is first-in-class drug in clinical trials for Rx of IFI due to Candida, Aspergillus and rare molds.
It is an inhibitor of the fungal enzyme Gwt1, with in vitro activity vs yeasts and molds, including Fusarium.
doi.org
#Olorofim is a novel drug with a mechanism through inhibition of dihydroorotate dehydrogenase in pyrimidine synthesis pathway.
It is active in vitro vs Aspergillus spp., rare molds (e.g., Lomentospora prolificans, Scedosporium spp., Scopulariopsis spp.) and Coccidioides spp.
#Rezafungin is a novel, once-weekly echinocandin developed for the treatment and prevention of serious fungal infections, including candidemia and invasive candidiasis.
It is not active against Fusarium.
#Ibrexafungerp is a first-in-class, triterpenoid antifungal agent used to treat vulvovaginal candidiasis (VVC), and to reduce the incidence of recurrent VVC in adults and adolescent females
It is not active against Fusarium.
doi.org

Loading suggestions...